Abstract
The treatment of rectal cancer usually involves total mesorectal excision, with preoperative chemoradiotherapy (CRT) that is aimed at downstaging tumors before surgical procedure. CRT response varies, with some patients completely responding to CRT and negating the need for surgery, and some patients not responding to the treatment at all. Identifying biomarkers of response to CRT would be beneficial in identifying whether a treatment would confer benefits to a patient while allowing them to avoid unnecessary morbidities and mortalities. While previous studies have attempted to identify such biomarkers, none have reached clinical utility which may be due to heterogeneity of the cancer. In this paper, we explored potential human gene and microbial biomarkers, and their possible contributions to the mechanisms of complete response to chemoradiotherapy. We carried out RNA sequencing on pairs of tumor and normal tissue from patients pre-surgery and analysed host gene expression and microbiome content. We discovered that the majority of enriched human genes in tumors of complete responders involve immunoglobulins, and enriched gene sets include complement and B-cell activation, and host response against viruses. This indicates involvement of immune responses in complete response to CRT. Among the enriched gene sets is the term defense response to bacterium, indicating a role of the microbiome in response to CRT. We discovered bacteria such as Ruminococcaceae bacterium and Bacteroides thetaiotaomicron to be abundant in tumors of complete responders. Both microbes have a history of being beneficial in treatment of cancers with immunotherapy, further emphasizing the role of immune responses in beneficial response to CRT. These results identify potential genetic and microbial biomarkers to CRT in rectal cancer, as well as offer a potential mechanism of complete response to CRT that may benefit further testing in the laboratory.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by The Health Research Council of New Zealand, Sir Charles Hercus Fellowship and Cancer Society of New Zealand.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for this work was given by the Health and Disability Ethics Committee of New Zealand (ethics approval number: 18/STH/40) and the Human Research Ethics Committees of Australia (ethics approval number: HREC 14/85).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Author list and corresponding affiliations and order updated
Data Availability
Raw sequences used in the study are available as BioProject ID PRJNA815861. The bioinformatics methodology is accessible at https://gitlab.com/schmeierlab/workflows/metafunc and further analyses at https://gitlab.com/alsulit08/uoc_response_rectalca.
https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA815861